Alaunos Therapeutics (TCRT) Insider Trading & Ownership $2.53 +0.29 (+12.95%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.41 -0.12 (-4.74%) As of 05/2/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alaunos Therapeutics (NASDAQ:TCRT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.11%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$487,500.00Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$9,513.00 Get TCRT Insider Trade Alerts Want to know when executives and insiders are buying or selling Alaunos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TCRT Insider Buying and Selling by Quarter Alaunos Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/1/2023Kevin S Sr. BoyleCEOSell453$21.00$9,513.00 11/29/2022Robert W PostmaDirectorBuy5,000$97.50$487,500.00 (Data available from 1/1/2013 forward) TCRT Insider Trading Activity - Frequently Asked Questions Who is on Alaunos Therapeutics's Insider Roster? The list of insiders at Alaunos Therapeutics includes Kevin S Sr. Boyle, and Robert W Postma. Learn more on insiders at TCRT. What percentage of Alaunos Therapeutics stock is owned by insiders? 5.11% of Alaunos Therapeutics stock is owned by insiders. Learn more on TCRT's insider holdings. Which Alaunos Therapeutics insiders have been selling company stock? The following insider sold TCRT shares in the last 24 months: Kevin S Sr. Boyle ($9,513.00). How much insider selling is happening at Alaunos Therapeutics? Insiders have sold a total of 453 Alaunos Therapeutics shares in the last 24 months for a total of $9,513.00 sold. Alaunos Therapeutics Key ExecutivesMr. Dale Curtis Hogue Jr. (Age 54)Interim CEO & Director Ms. Melinda Lackey (Age 47)Senior VP of Legal, Administration & Secretary Compensation: $625.12kMr. Michael Wong (Age 44)Vice President of Finance & Principal Accounting Officer More Insider Trading Tools from MarketBeat Related Companies Equillium Insider Trades Bullfrog AI Insider Trades BioVie Insider Trades GlycoMimetics Insider Trades MIRA Pharmaceuticals Insider Trades Relmada Therapeutics Insider Trades IN8bio Insider Trades Moleculin Biotech Insider Trades Cellectar Biosciences Insider Trades Cocrystal Pharma Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:TCRT) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
